Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.22.4
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
REVENUES        
Government contract revenue $ 0 $ 17,117 $ 0 $ 281,049
OPERATING EXPENSES        
Professional fees 729,665 433,404 2,575,496 1,666,333
Payroll and related expenses 1,048,761 999,500 3,191,402 2,821,850
General and administrative 1,071,327 1,112,159 3,653,832 2,428,053
Total operating expenses 2,849,753 2,545,063 9,420,730 6,916,236
OPERATING LOSS (2,849,753) (2,527,946) (9,420,730) (6,635,187)
OTHER EXPENSE        
Loss on dissolution of subsidiary 0 0 142,121 0
NET LOSS (2,849,753) (2,527,946) (9,562,851) (6,635,187)
LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS 0 (2,214) 0 (4,174)
NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC. $ (2,849,753) $ (2,525,732) $ (9,562,851) $ (6,631,013)
BASIC LOSS PER SHARE $ (0.12) $ (0.16) $ (0.48) $ (0.46)
DILUTED LOSS PER SHARE $ (0.12) $ (0.16) $ (0.48) $ (0.46)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC 22,946,483 15,397,418 19,741,451 14,543,787
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – DILUTED 22,946,483 15,397,418 19,741,451 14,543,787